title: Osteopontin promotes pathologic mineralization in articular cartilage.
abstract: Calcium pyrophosphate dihydrate (CPPD) crystals are commonly found in osteoarthritic joint tissues, where they predict severe disease. Unlike other types of calcium phosphate crystals, CPPD crystals form almost exclusively in the pericellular matrix of damaged articular cartilage, suggesting a key role for the extracellular matrix milieu in their development. Osteopontin is a matricellular protein found in increased quantities in the pericellular matrix of osteoarthritic cartilage. Osteopontin modulates the formation of calcium-containing crystals in many settings. We show here that osteopontin stimulates ATP-induced CPPD crystal formation by chondrocytes in vitro. This effect is augmented by osteopontin's incorporation into extracellular matrix by transglutaminase enzymes, is only modestly affected by its phosphorylation state, and is inhibited by integrin blockers. Surprisingly, osteopontin stimulates transglutaminase activity in cultured chondrocytes in a dose-responsive manner. As elevated levels of transglutaminase activity promote extracellular matrix changes that permit CPPD crystal formation, this is one possible mechanism of action. We demonstrate the presence of osteopontin in the pericellular matrix of chondrocytes adjacent to CPPD deposits and near active transglutaminases. Thus, osteopontin may play an important role in facilitating CPPD crystal formation in articular cartilage.
authors.affiliation: The Division of Rheumatology, Department of Medicine, Medical College of Wisconsin and the Zablocki VA Medical Center, Milwaukee, WI 53295-1000, USA. ann.rosenthal@med.va.gov
authors.forename: Ann K
authors.initials: AK
authors.lastname: Rosenthal
authors.forename: Claudia M
authors.initials: CM
authors.lastname: Gohr
authors.forename: Miwa
authors.initials: M
authors.lastname: Uzuki
authors.forename: Ikuko
authors.initials: I
authors.lastname: Masuda
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D002103:Cadaverine / Q000031:analogs & derivatives / Q000494:pharmacology; D002114:Calcinosis / Q000378:metabolism*; D002131:Calcium Pyrophosphate / Q000378:metabolism*; D002358:Cartilage, Articular / Q000378:metabolism*; D019902:Chondrocytes / Q000378:metabolism*; D003538:Cystamine / Q000494:pharmacology; D011756:Diphosphates / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005109:Extracellular Matrix / Q000378:metabolism; D007150:Immunohistochemistry; D053495:Osteopontin / Q000378:metabolism*; D034421:Sus scrofa; D013917:Thrombin / Q000378:metabolism; D011503:Transglutaminases / Q000037:antagonists & inhibitors
chemical_list: D011756:Diphosphates; D053495:Osteopontin; D000255:Adenosine Triphosphate; D011503:Transglutaminases; D013917:Thrombin; C008542:monodansylcadaverine; D002103:Cadaverine; D003538:Cystamine; D002131:Calcium Pyrophosphate